MAIA Biotechnology has reported positive initial efficacy results from its Phase II THIO-101 trial, Part C, involving its ...

The panel discusses the full multidisciplinary team required to optimize outcomes for patients with ROS1-positive advanced ...

MAIA recently announced that it has completed international enrollment in Part C of the Phase 2 THIO-101 expansion trial. Treatment with ateganosine followed by cemiplimab has shown an acceptable ...

Abbisko will lead the study, with both companies jointly sharing clinical trial responsibilities.

The second clinical case presents a patient with ROS1 fusion-positive advanced NSCLC who achieved partial response on ...

Divarasib outperformed existing therapies in patients with KRAS G12C non-small cell lung cancer (NSCLC).

Breakthrough research led by scientists in Manchester has identified a new drug combination that could improve outcomes for ...

Survival in the transplant group was also similar to a cohort of non-cancer patients who underwent lung transplantation for ...

If you have non-small-cell lung cancer (NSCLC) with an EGFR mutation, your health care provider may recommend a new medicine called Datroway (datopotamab deruxtecan-dlnk). NSCLC is the most common ...

Recently published Non-small Cell Lung Cancer Market Insights report includes a comprehensive understanding of current ...

Your treatment journey for non-small-cell lung cancer (NSCLC) may vary from that of others with the same diagnosis. But you’ll likely start with some of the same treatments. You’ll have lots of ...

Key market opportunities in lung cancer therapeutics include the rising incidence of lung cancer, innovations in therapeutics ...